 |
Building great companies through active collaboration
GIMV’s Life Sciences division targets innovative biotech companies that are developing first-in-class and best-in-class products for growth markets. Given the strongly cyclical nature of the biotech sector, it is important that we invest with a long term vision. The period between investment and potential exit is often very long, unpredictable and capital-intensive.
At management level we seek active involvement. Together with the management and co-investors of the shareholding in question, our team contributes to creating value in the company. In so doing we maximize the return on the investment.
Depending on market circumstances, all phases of company development can be considered for potential investment.Start-ups and later stagecompanies, including spin-outs and listed companies are all eligible. The investment opportunities that we assess cover a broad range of activities, including drug discovery and development, diagnostics, medical devices and medical services.
Our team is aiming at a diversified portfolio. This enables us to spread the risk more widely, which is important in a volatile sector like biotechnology. Such an investment policy also produces more stable returns.
Geographically too, we have opted for a balanced portfolio, but with a clear European focus.
|